派姆单抗-话题@MedSci

#派姆单抗#

82篇内容 | 3710人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2130150, encodeId=63d8213015084, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>联合化疗联合或不联合<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>治疗持续性、复发性或转移性<a href='/topic/show?id=146246308d1' target=_blank style='color:#2F92EE;'>#宫颈癌#</a><a href='/topic/show?id=e56a48488ce' target=_blank style='color:#2F92EE;'>#帕妥珠单抗#</a>, objectTitle=2023 NICE 技术鉴定指导意见：派姆单抗联合化疗联合或不联合贝伐单抗治疗持续性、复发性或转移性宫颈癌[TA885], objectType=guider, longId=23848, objectId=c7d921c003120978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=c7d921c003120978, replyNumber=0, likeNumber=152, createdTime=2023-05-05, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c7d921c003120978, moduleTitle=2023 NICE 技术鉴定指导意见：派姆单抗联合化疗联合或不联合贝伐单抗治疗持续性、复发性或转移性宫颈癌[TA885], moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=c7d921c003120978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2104406, encodeId=157821044064a, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>作为二线可有效治疗晚期<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>, objectTitle=J Clin Oncol：派姆单抗作为二线可有效治疗晚期肝癌, objectType=article, longId=750675, objectId=1e3fe506750e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221205/1670211887590_2110107.JPG, objectUrl=/article/show_article.do?id=1e3fe506750e, replyNumber=0, likeNumber=151, createdTime=2022-12-05, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1e3fe506750e, moduleTitle=J Clin Oncol：派姆单抗作为二线可有效治疗晚期肝癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e3fe506750e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2098471, encodeId=fad620984e103, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>KEYNOTE-042是一项三期的随机试验，初期结果显示派姆单抗单药治疗相比以铂类为基础的化疗显著延长了既往未治疗过的PD-L1肿瘤比例评分（TPS）≥1%的局部晚期或转移性非小细胞肺癌（NSCLC）患者的总生存期（OS）。, objectTitle=派姆单抗, objectType=topic, longId=65265, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=72, createdTime=2022-11-04, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2089208, encodeId=df7f208920838, content=与安慰剂相比，<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a><a href='/topic/show?id=89a810615bb' target=_blank style='color:#2F92EE;'>#K药#</a>显著延长了完全切除的IB-IIIA期<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>患者的无病生存期，无论<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>表达水平如何，而且无新的安全性问题。派姆单抗可作为完全切除后的IB-IIIA期NSCLC患者的新治疗选择。说明术后辅助也是有效的，那么如果术前做<a href='/topic/show?id=1a5a58e00ad' target=_blank style='color:#2F92EE;'>#新辅助治疗#</a>，术后再做一段时间辅助，会不会更好？？, objectTitle=Lancet Oncol：派姆单抗辅助治疗可显著延长术后IB-IIIA期NSCLC患者的生存期, objectType=article, longId=740057, objectId=aad8e40057a1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220919/1663595268646_2110107.JPG, objectUrl=/article/show_article.do?id=aad8e40057a1, replyNumber=0, likeNumber=161, createdTime=2022-09-20, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aad8e40057a1, moduleTitle=Lancet Oncol：派姆单抗辅助治疗可显著延长术后IB-IIIA期NSCLC患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aad8e40057a1)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1253500, encodeId=2dde1253500e4, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Lancet Oncol：派姆单抗单药辅助治疗术后高复发风险的肾透明细胞癌, objectType=article, longId=737794, objectId=6a68e377947e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a68e377947e, replyNumber=0, likeNumber=124, createdTime=2022-09-06, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a68e377947e, moduleTitle=Lancet Oncol：派姆单抗单药辅助治疗术后高复发风险的肾透明细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a68e377947e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253499, encodeId=88db1253499cd, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=J Clin Oncol：Talimogene Laherparepvec联合派姆单抗治疗晚期黑色素瘤, objectType=article, longId=737793, objectId=5560e37793d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5560e37793d5, replyNumber=0, likeNumber=134, createdTime=2022-09-06, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5560e37793d5, moduleTitle=J Clin Oncol：Talimogene Laherparepvec联合派姆单抗治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5560e37793d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253497, encodeId=a964125349e01, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Ann Oncol：派姆单抗治疗多种MSI-H/dMMR实体肿瘤的疗效和安全性, objectType=article, longId=729827, objectId=8d36e298275b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d36e298275b, replyNumber=0, likeNumber=103, createdTime=2022-06-19, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d36e298275b, moduleTitle=Ann Oncol：派姆单抗治疗多种MSI-H/dMMR实体肿瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d36e298275b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253496, encodeId=d9eb12534968c, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=J Clin Oncol：雷莫芦单抗联合派姆单抗治疗晚期非小细胞肺癌, objectType=article, longId=728627, objectId=e0bce2862724, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0bce2862724, replyNumber=0, likeNumber=110, createdTime=2022-06-06, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0bce2862724, moduleTitle=J Clin Oncol：雷莫芦单抗联合派姆单抗治疗晚期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0bce2862724)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253498, encodeId=f13b12534988d, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后, objectType=article, longId=728384, objectId=e24ae28384d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e24ae28384d8, replyNumber=0, likeNumber=98, createdTime=2022-06-02, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e24ae28384d8, moduleTitle=2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e24ae28384d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253495, encodeId=1bd612534950f, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Clin Cancer Res：派姆单抗单药治疗初治晚期肝细胞癌, objectType=article, longId=726090, objectId=0c95e260900a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c95e260900a, replyNumber=0, likeNumber=80, createdTime=2022-05-05, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c95e260900a, moduleTitle=Clin Cancer Res：派姆单抗单药治疗初治晚期肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c95e260900a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253494, encodeId=53611253494ed, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Lancet Oncol：派姆单抗 vs 化疗治疗微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的长期预后, objectType=article, longId=724610, objectId=793de2461036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=793de2461036, replyNumber=0, likeNumber=98, createdTime=2022-04-21, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=793de2461036, moduleTitle=Lancet Oncol：派姆单抗 vs 化疗治疗微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=793de2461036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253493, encodeId=df8c12534930a, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=J Clin Oncol：采用派姆单抗±化疗治疗复发性/转移性头颈部鳞癌, objectType=article, longId=302189, objectId=e07a302189c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e07a302189c4, replyNumber=0, likeNumber=111, createdTime=2022-04-03, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e07a302189c4, moduleTitle=J Clin Oncol：采用派姆单抗±化疗治疗复发性/转移性头颈部鳞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e07a302189c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253492, encodeId=5900125349219, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Lancet Oncol：派姆单抗治疗经典或地方性卡波西肉瘤的疗效, objectType=article, longId=300991, objectId=5bf030099141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bf030099141, replyNumber=0, likeNumber=0, createdTime=2022-03-18, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bf030099141, moduleTitle=Lancet Oncol：派姆单抗治疗经典或地方性卡波西肉瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bf030099141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253491, encodeId=26921253491b2, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=NEJM：手术前后加用派姆单抗可显著提高早期三阴性乳腺癌的生存率, objectType=article, longId=295536, objectId=2e43295536c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e43295536c6, replyNumber=0, likeNumber=116, createdTime=2022-02-14, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e43295536c6, moduleTitle=NEJM：手术前后加用派姆单抗可显著提高早期三阴性乳腺癌的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e43295536c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253490, encodeId=7c5e125349093, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Clin Cancer Res：SD-101联合派姆单抗治疗复发/转移性鳞状细胞癌, objectType=article, longId=295436, objectId=e084295436ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e084295436ca, replyNumber=0, likeNumber=127, createdTime=2022-02-12, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e084295436ca, moduleTitle=Clin Cancer Res：SD-101联合派姆单抗治疗复发/转移性鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e084295436ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253489, encodeId=49a71253489c5, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, objectType=article, longId=295140, objectId=2fc82951409c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fc82951409c, replyNumber=0, likeNumber=110, createdTime=2022-02-06, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fc82951409c, moduleTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fc82951409c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253488, encodeId=412e1253488eb, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=NEJM：乐伐替尼加派姆单抗治疗晚期子宫内膜癌, objectType=article, longId=295126, objectId=f06e2951268b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f06e2951268b, replyNumber=0, likeNumber=120, createdTime=2022-02-06, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f06e2951268b, moduleTitle=NEJM：乐伐替尼加派姆单抗治疗晚期子宫内膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f06e2951268b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253487, encodeId=492d125348e64, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=J Clin Oncol：派姆单抗治疗不稳定性高的晚期子宫内膜癌的疗效, objectType=article, longId=294803, objectId=6aaf29480333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aaf29480333, replyNumber=0, likeNumber=91, createdTime=2022-01-28, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aaf29480333, moduleTitle=J Clin Oncol：派姆单抗治疗不稳定性高的晚期子宫内膜癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aaf29480333)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253486, encodeId=534112534868b, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Eur Urol：立体定向放疗和短期派姆单抗治疗寡转移性肾细胞癌的疗效和安全性评估 , objectType=article, longId=293393, objectId=a91729339309, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91729339309, replyNumber=0, likeNumber=107, createdTime=2022-01-05, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91729339309, moduleTitle=Eur Urol：立体定向放疗和短期派姆单抗治疗寡转移性肾细胞癌的疗效和安全性评估 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91729339309)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253485, encodeId=85ed12534851e, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Clin Cancer Res：派姆单抗联合Acalabrutinib治疗复发/转移性头颈鳞状细胞癌 , objectType=article, longId=221637, objectId=357d22163ea7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=357d22163ea7, replyNumber=0, likeNumber=95, createdTime=2021-12-08, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=357d22163ea7, moduleTitle=Clin Cancer Res：派姆单抗联合Acalabrutinib治疗复发/转移性头颈鳞状细胞癌 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=357d22163ea7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

派姆单抗

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

#派姆单抗#联合化疗联合或不联合#贝伐单抗#治疗持续性、复发性或转移性#宫颈癌##帕妥珠单抗#

2023 NICE 技术鉴定指导意见：派姆单抗联合化疗联合或不联合贝伐单抗治疗持续性、复发性或转移性宫颈癌[TA885]

2023-05-05发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

#派姆单抗#作为二线可有效治疗晚期#肝癌#

J Clin Oncol：派姆单抗作为二线可有效治疗晚期肝癌

2022-12-05发表于上海

yangchou (审核中...)

前往app查看评论内容

#派姆单抗#KEYNOTE-042是一项三期的随机试验，初期结果显示派姆单抗单药治疗相比以铂类为基础的化疗显著延长了既往未治疗过的PD-L1肿瘤比例评分（TPS）≥1%的局部晚期或转移性非小细胞肺癌（NSCLC）患者的总生存期（OS）。

2022-11-04

小小医者 (审核中...)

前往app查看评论内容

全文收起与安慰剂相比，#派姆单抗##K药#显著延长了完全切除的IB-IIIA期#NSCLC#患者的无病生存期，无论#PD-L1#表达水平如何，而且无新的安全性问题。派姆单抗可作为完全切除后的IB-IIIA期NSCLC患者的新治疗选择。说明术后辅助也是有效的，那么如果术前做#新辅助治疗#，术后再做一段时间辅助，会不会更好？？

Lancet Oncol：派姆单抗辅助治疗可显著延长术后IB-IIIA期NSCLC患者的生存期

2022-09-20

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Lancet Oncol：派姆单抗单药辅助治疗术后高复发风险的肾透明细胞癌

2022-09-06

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

J Clin Oncol：Talimogene Laherparepvec联合派姆单抗治疗晚期黑色素瘤

2022-09-06

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Ann Oncol：派姆单抗治疗多种MSI-H/dMMR实体肿瘤的疗效和安全性

2022-06-19

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

J Clin Oncol：雷莫芦单抗联合派姆单抗治疗晚期非小细胞肺癌

2022-06-06

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后

2022-06-02

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Clin Cancer Res：派姆单抗单药治疗初治晚期肝细胞癌

2022-05-05

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Lancet Oncol：派姆单抗 vs 化疗治疗微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的长期预后

2022-04-21

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

J Clin Oncol：采用派姆单抗±化疗治疗复发性/转移性头颈部鳞癌

2022-04-03

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Lancet Oncol：派姆单抗治疗经典或地方性卡波西肉瘤的疗效

2022-03-18

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

NEJM：手术前后加用派姆单抗可显著提高早期三阴性乳腺癌的生存率

2022-02-14

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Clin Cancer Res：SD-101联合派姆单抗治疗复发/转移性鳞状细胞癌

2022-02-12

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？

2022-02-06

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

NEJM：乐伐替尼加派姆单抗治疗晚期子宫内膜癌

2022-02-06

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

J Clin Oncol：派姆单抗治疗不稳定性高的晚期子宫内膜癌的疗效

2022-01-28

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Eur Urol：立体定向放疗和短期派姆单抗治疗寡转移性肾细胞癌的疗效和安全性评估

2022-01-05

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Clin Cancer Res：派姆单抗联合Acalabrutinib治疗复发/转移性头颈鳞状细胞癌

2021-12-08

科室
- - 订阅+
  - 更多科室
工具
服务